logo
Share SHARE
FONT-SIZE Plus   Neg

Biogen: US And EU Regulators Accept Plegridy Marketing Applications For Review

Biogen Idec (BIIB) announced Friday that U.S. and EU regulatory authorities have accepted the marketing applications for the review of Plegridy (peginterferon beta-1a), the company's pegylated subcutaneous injectable candidate for relapsing forms of multiple sclerosis or MS.

The U.S. Food and Drug Administration or FDA has accepted Biogen Idec's Biologics License Application or BLA for marketing approval of Plegridy in the United States and granted the company a standard review timeline. The Marketing Authorisation Application or MAA of Plegridy for review in the European Union was also validated by the European Medicines Agency.

The regulatory applications included positive one-year results from the two-year global Phase 3 Advance study. The data demonstrated that PLEGRIDY met all primary and secondary endpoints by significantly reducing disease activity including relapses, disability progression and brain lesions compared to placebo, and showed favorable safety and tolerability profiles at one year.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
After falling sharply in early trading, stocks showed a substantial turnaround over the course of the trading session on Tuesday. The major averages bounced well off their lows for the session and into positive territory. Coca-Cola announced that it is removing its trademark logo from cans in the Middle East as part of the soda giant's marketing campaign to fight prejudice. The company has replaced its famous trademark logo with "Labels are for cans not people," message. The company has made the change during the... Carnival said it has obtained U.S. approval to begin cruises to Cuba. The announcement by the cruise operator follows the recent restoration of diplomatic relations between the U.S. and Cuba.
comments powered by Disqus
RELATED NEWS
Trade BIIB now with 
Follow RTT